RxDoctor Payments Data

John Billingsley, MD

Ophthalmology · Siloam Springs, ARNPI 1972569382

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,420 of the $2,135 with a category attached, or 66.5%. 13 manufacturers reported payments, led by Biotissue Holdings Inc. at 33.7% of the total. Reporting peaked in 2019 at $1,002 and has fallen 93.9% since, to $61 in 2024.

$2,135in general payments, 2019–2025

Across 41 payments — averaging $52.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$719
  • Alcon$572
  • Carl Zeiss Meditec USA, Inc.$332
  • AbbVie$194
  • Sun Pharmaceutical Industries Inc.$97
  • Novartis$94
  • plus $126 from 7 others

What the payments were for

  • Consulting fees$63030%
  • Food & beverage$1,42067%
  • Education$402%
  • Gifts$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,135 in reported general payments places this provider in the 80th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$60,473
Medicare patients
207
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate19$684
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$502
Latanoprost52$257

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Siloam Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →